Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We thank Samson et al for their interest in our article on ustekinumab in giant-cell arteritis (GCA) and for their comments on our study.1 2 Our initial pilot study reported promising results with the use of ustekinumab in refractory GCA.1
GCA is associated with considerable disease-related and treatment-related morbidity.3 4 While glucocorticoids remain the cornerstone of treatment, the associated increased rates of adverse events such as fractures, sepsis, hypertension and diabetes mellitus are significant concerns to both physicians and patients.4 There is a critical unmet need for new treatment options in GCA to minimise the cumulative glucocorticoid burden …
Contributors All authors contributed to the manuscript and approved the final version.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Data sharing statement Data used in this study are held in Bone and Joint Unit, St. Vincent’s University Hospital, Dublin, Ireland, under the custody of EM and can be made available on request.